Page 94 - 《中国药房》2022年23期

setting[J]. Thromb J，2016，14：8. favourable safety profile in subgroups with different BMI，
[18] TANG A，SICAT C S，SINGH V，et al. Aspirin use for ve‐ renal function and age[J]. Blood，2012，120（21）：1160.
nous thromboembolism prevention is safe and effective in [30] YI Y H，GONG S，GONG T L，et al. New oral anticoagu‐
overweight and obese patients undergoing revision total lants for venous thromboembolism prophylaxis in total
hip and knee arthroplasty[J]. J Arthroplasty，2021，36 hip and knee arthroplasty：a systematic review and net‐
（7S）：S337-S344. work meta-analysis[J]. Front Pharmacol，2021，12：775126.
[19] TURPIE A G G，LASSEN M R，ERIKSSON B I，et al. Ri‐ [31] 凌涛，徐瑞娟，王斌，等. 新型口服抗凝剂用于关节置换
varoxaban for the prevention of venous thromboembolism 术后有效性和安全性的系统评价[J]. 中国循证医学杂
after hip or knee arthroplasty. Pooled analysis of four studies 志，2020，20（9）：1038-1044.
[J]. Thromb Haemost，2011，105（3）：444-453. [32] COHEN A T，PAN S，BYON W，et al. Efficacy，safety，
[20] ERIKSSON B I，DAHL O E，ROSENCHER N，et al. and exposure of apixaban in patients with high body
Dabigatran etexilate versus enoxaparin for prevention of weight or obesity and venous thromboembolism：insights
venous thromboembolism after total hip replacement：a from AMPLIFY[J]. Adv Ther，2021，38（6）：3003-3018.
randomised，double-blind，non-inferiority trial[J]. Lancet， [33] NOVAK A R，SHAKOWSKI C，TRUJILLO T C，et al.
2007，370（9591）：949-956. Evaluation of safety and efficacy outcomes of direct oral
[21] ERIKSSON B I，DAHL O E，ROSENCHER N，et al. Oral anticoagulants versus warfarin in normal and extreme
dabigatran etexilate vs. subcutaneous enoxaparin for the body weights for the treatment of atrial fibrillation or ve‐
prevention of venous thromboembolism after total knee re‐ nous thromboembolism[J]. J Thromb Thrombolysis，2022，
placement：the RE-MODEL randomized trial[J]. J Thromb 54（2）：276-286.
Haemost，2007，5（11）：2178-2185. [34] MARTIN K A，BEYER-WESTENDORF J，DAVIDSON
[22] ERIKSSON B I，BORRIS L C，FRIEDMAN R J，et al. Ri‐ B L，et al. Use of direct oral anticoagulants in patients
varoxaban versus enoxaparin for thromboprophylaxis with obesity for treatment and prevention of venous
after hip arthroplasty[J]. N Engl J Med，2008，358（26）： thromboembolism：updated communication from the
2765-2775. ISTH SSC Subcommittee on Control of Anticoagulation
[23] KAKKAR A K，BRENNER B，DAHL O E，et al. Ex‐ [J]. J Thromb Haemost，2021，19（8）：1874-1882.
tended duration rivaroxaban versus short-term enoxaparin [35] ALOI K G，FIERRO J J，STEIN B J，et al. Investigation
for the prevention of venous thromboembolism after total of direct-acting oral anticoagulants and the incidence of
hip arthroplasty：a double-blind，randomised controlled venous thromboembolism in patients weighing ≥120 kg
trial[J]. Lancet，2008，372（9632）：31-39. compared to patients weighing ＜120 kg[J]. J Pharm
[24] LASSEN M R，AGENO W，BORRIS L C，et al. Rivaroxa‐ Pract，2021，34（1）：64-69.
ban versus enoxaparin for thromboprophylaxis after total [36] HALBUR C R，GULBRANDSEN T R，WEST C R，et al.
knee arthroplasty[J]. N Engl J Med，2008，358（26）：2776- Weight-based aspirin dosing may further reduce the inci‐
2786. dence of venous thromboembolism following primary
[25] TURPIE A G，LASSEN M R，DAVIDSON B L，et al. Ri‐ total joint arthroplasty[J]. J Arthroplasty，2021，36（12）：
varoxaban versus enoxaparin for thromboprophylaxis 3986-3992.
after total knee arthroplasty （RECORD4）：a randomised [37] ROCCA B，FOX K A A，AJJAN R A，et al. Antithrom‐
trial[J]. Lancet，2009，373（9676）：1673-1680. botic therapy and body mass：an expert position paper of
[26] LASSEN M R，GALLUS A，RASKOB G E，et al. Apixa‐ the ESC Working Group on Thrombosis[J]. Eur Heart J，
ban versus enoxaparin for thromboprophylaxis after hip re‐ 2018，39（19）：1672-1686f.
placement[J]. N Engl J Med，2010，363（26）：2487-2498. [38] HUMPHREY T J，O'BRIEN T D，MELNIC C M，et al.
[27] LASSEN M R，RASKOB G E，GALLUS A，et al. Apixa‐ Morbidly obese patients undergoing primary total joint ar‐
ban versus enoxaparin for thromboprophylaxis after knee throplasty may experience higher rates of venous thromboem-
replacement （ADVANCE-2）：a randomised double-blind bolism when prescribed direct oral anticoagulants vs aspirin
trial[J]. Lancet，2010，375（9717）：807-815. [J]. J Arthroplasty，2022，37（6）：1189-1197.
[28] ERIKSSON B I，DAHL O E，HUO M H，et al. Oral dabi‐ [39] LEWIS S，GLEN J，DAWOUD D，et al. Venous thrombo‐
gatran versus enoxaparin for thromboprophylaxis after pri‐ embolism prophylaxis strategies for people undergoing
mary total hip arthroplasty （RE-NOVATE Ⅱ *）. A ran‐ elective total knee replacement：a systematic review and
domised，double-blind，non-inferiority trial[J]. Thromb network meta-analysis[J]. Lancet Haematol，2019，6（10）：
Haemost，2011，105（4）：721-729. e530-e539.
[29] ROSENCHER N，FROSTICK S，FEURING M，et al. （收稿日期：2022-07-28 修回日期：2022-10-09）
Real-world study of dabigatran etexilate for thrombopro‐ （编辑：舒安琴）
phylaxis in over 5 000 hip or knee replacement patients：

· 2900 · China Pharmacy 2022 Vol. 33 No. 23 中国药房 2022年第33卷第23期